AstraZeneca: indications for Faslodex drug broadened.

(CercleFinance.com) - AstraZeneca said on Tuesday that the European Commission has approved a new indication for Faslodex for the treatment of advanced breast cancer in combination with Pfizer's Palbociclib.


More specifically, Brussels' decision relates to the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.

For many years Faslodex has been used as a monotherapy treatment alone for women with hormone receptor positive breast cancer.

AstraZeneca said the EU approval is based on phase III trial which showed an increase in progression-free survival of 4.9 months (9.5 months vs 4.6 months) in patients who received the medicine.

Copyright (c) 2017 CercleFinance.com. All rights reserved.